FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
10 letters match. Newest first.
-
DrugsEmpower Clinic Services, LLC dba Empower Pharmacy
FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.
High risk -
DrugsAltru Telehealth, LLC dba Altru Telehealth
FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.
Low -
DrugsPublic Health Solution LLC dba DrMedHealth
FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.
Low -
DrugsEzra Holdco LLC dba Ezra
FDA says Ezra's website misbrands compounded semaglutide and tirzepatide by labeling them as Ezra-made when they are not.
Low -
DrugsReady Med
FDA warned Ready Med over website claims that compounded semaglutide and tirzepatide products were FDA-approved or FDA-licensed.
Low -
DrugsStrut Health, LLC dba Strut
FDA says Strut Health's website falsely labeled compounded semaglutide and tirzepatide as its own and FDA-approved.
Low -
DrugsAlan Health Technologies Inc. dba Alan
FDA warns Alan Health Technologies over website falsely labeling compounded semaglutide and tirzepatide as Alan-made.
Low -
DrugsDripgym Mobile Parent, LLC dba Amp Health
FDA warned Amp Health that its website misbranded compounded semaglutide and tirzepatide with false maker and approval-implying claims.
Low -
DrugsBliv Wellness LLC dba Bliv
FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsBluefitMD
FDA warned BluefitMD that its website falsely labels compounded semaglutide and tirzepatide as its own and as FDA-approved.
Low